Polymorphic Forms of Potassium Channel Modulator for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to develop and understand the solid state crystalline forms of Compound A, particularly for its therapeutic use in treating seizure disorders, as existing forms may not offer optimal processing properties, stability, or efficacy.
Innovation Solution
The disclosure focuses on the development of various solid state crystalline forms of Compound A, including Forms 1 through 11, along with methods for their preparation and pharmaceutical compositions containing these forms, to enhance therapeutic effectiveness and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing solid state forms of Compound A are used, then the compound can be administered for therapeutic use, but the processing properties and stability are not optimal
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing multiple polymorphic forms (Forms 1-11) of Compound A, each with distinct crystal structures and physical properties. By changing the solid state parameters (crystal packing, molecular conformation, intermolecular interactions), the invention achieves optimal combinations of stability and processing properties for therapeutic use
Solution Approach 2:
The patent creates composite solid state forms by forming specific crystalline structures with defined molecular arrangements and intermolecular interactions. These composite crystal structures combine multiple molecular components in specific spatial configurations to achieve enhanced stability and processing characteristics
2Manufacturing precision
If multiple solid state crystalline forms are developed, then processing and stability are improved, but the complexity of characterization and selection increases
Solution Approach 1:
The patent segments the solid state forms into distinct, numbered polymorphic forms (Forms 1-11), each with uniquely identified characteristics. This segmentation allows systematic characterization and selection of specific forms based on desired properties, reducing the complexity of managing multiple forms by organizing them into discrete, well-defined categories
Solution Approach 2:
The patent employs spectroscopic techniques (infrared absorption, solid state NMR, X-ray diffraction) that detect characteristic spectral 'signatures' or 'colors' for each polymorphic form. These spectral characteristics serve as unique identifiers that simplify the characterization and differentiation of multiple solid state forms
3Reliability
If solid state crystalline forms are optimized for therapeutic efficacy, then the treatment effectiveness improves, but the development time and resources increase
Solution Approach 1:
The patent performs preliminary characterization and selection of optimal solid state forms (Forms 1-11) with desired therapeutic properties before clinical development. By pre-identifying and characterizing the most promising polymorphic forms with optimal pharmacokinetic and pharmacodynamic profiles, the invention reduces development time by avoiding later-stage form optimization issues
Data Source
AI summary
The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.